TYRA

Tyra Biosciences, Inc. [TYRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TYRA Stock Summary

Top 10 Correlated ETFs

TYRA

Top 10 Correlated Stocks

TYRA

In the News

TYRA Financial details

Company Rating
-
Market Cap
782.04M
Income
-66.68M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-20.64
Forward P/E
-
PEG
-7.93
P/S
-
P/B
2.26
P/C
-
P/FCF
-10.32
Quick Ratio
21.25
Current Ratio
22.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.55
EPS next Y
-
EPS next Q
-
EPS this Y
31.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
8.16%
-
-
-
-
SMA20
-21.26%
SMA50
-19.5%
SMA100
-46.36%
Inst Own
-
Inst Trans
-
ROA
-10%
ROE
-38%
ROC
-0.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.38-20.67
52W High
-34.15%
52W Low
+31.7%
RSI
43.64
Rel Volume
1.5
Avg Volume
134.91K
Volume
202.65K
Perf Week
8.57%
Perf Month
-17.43%
Perf Quarter
-38.26%
Perf Half Y
-41.93%
-
-
-
-
Beta
1.123
-
-
Volatility
0.4%, 1.49%
Prev Close
3.05%
Price
13.17
Change
2.57%

Something similar

Top by Market Cap
TSLA
VTI
VFINX
MSFT
ABEA.DE
Top Correlated ETFs
DUST
JDST
GDXD
GLL
BTF
Top Correlated Stocks
INTV
RHI
NVCR
DOOO
0KEQ.L
Similar Market Cap
ACT.DE
0621.HK
NAXS.ST
FDUS
UHT

Company Profile

Healthcare Biotechnology
  • Volume Average 134.91K
  • Market Capitalization 782.04M
  • Employee 49
  • CEO Dr. Todd Harris Ph.D.
  • Headquarters Carlsbad,CA,US
  • IPO Date 2021-09-15
  • Website https://www.tyra.bio

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.